On December 30, 2025, injected GLP-1 treatments revolutionized how obesity is managed—and now, they're becoming available in an oral format.
The FDA has just given the green light to a tablet variant of semaglutide, known as Wegovy, aimed at aiding weight reduction and lowering risks of serious cardiovascular incidents such as heart attacks and strokes. This approval represents the inaugural clearance in the U.S. for a GLP-1 medication specifically for managing body weight.
The Wegovy tablet is slated for release in January. (A different oral GLP-1 agent, orforglipron, remains under accelerated FDA review and might become accessible for weight control soon.)
"Providing additional choices for individuals dealing with obesity is beneficial," remarked Melanie Jay, MD, an associate professor at NYU Grossman School of Medicine.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
She noted that numerous patients favor tablets over syringes. Specialists are detailing the differences between these delivery methods.
The Wegovy tablet consists of a swallowable pill, whereas the injection form requires administration via a needle, typically into the thigh or abdominal region.
Health tracking apps like Shotlee can assist in monitoring advancements during such treatments.